To investigate these two issues, we studied the effect of the B-cell specific, CD47/CD19 immune checkpoint blocker, TG-1801, in association with anti-CD20/PI3Kδi dual therapy in different in vitro and in vivo models of BL, as a disease model of aggressive B-NHL. This evidence concerns the gene CD47 and Burkitt lymphoma.